Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report

Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report

Abstract Background Brentuximab vedotin (BV) is an antibody–drug conjugate formed by an anti-CD30 chimeric IgG1 conjugated with monomethyl-auristatin-E. BV targets the CD30+ cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30+ cells BV exerts...

Full description

Bibliographic Details
Main Authors: Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Clinical and Molecular Allergy
Subjects:
Anti CD30
Auristatin-E
Hodgkin lymphoma
Desensitization
Monoclonal antibodies
Drug allergy
Online Access:http://link.springer.com/article/10.1186/s12948-018-0100-0

Internet

http://link.springer.com/article/10.1186/s12948-018-0100-0

Similar Items